Dr. Maciej Michal Mrugala on the Efficacy and Further Uses of Temozolomide in Gliomas
Maciej Michal Mrugala MD, PhD, MPH, chief of the Division of Neuro-Oncology, University of Washington
Maciej Michal Mrugala MD, PhD, MPH, chief of the Division of Neuro-Oncology, University of Washington’s School of Medicine, discusses the efficacy of temozolomide in gliomas. Mrugala says temozolomide is one of the few treatments that can effectively cross the blood-brain barrier, and is more bioavailable than most other treatments.
Mrugala adds that there are currently ongoing tests to study the efficacy of temozolomide given locally in animal models. He adds there are also studies looking into placing temozolomide into a polymer, which in turn would be placed into the resection cavity as another way of administering treatment.
Need for Systemic Therapy Remains in Sarcoma
November 27th 2023In an interview with Targeted Oncology, Lisa B. Ercolano, MD, discussed the evolving treatment landscape for sarcomas and underscored the pivotal role of molecular profiling, while addressing the need for more efficacious systemic therapies.
Read More
BRUIN MCL-321 Trial Evaluates Pirtobrutinb Monotherapy in MCL
November 20th 2023In an interview with Targeted Oncology, Michael Wang, MD, discussed the rationale of the phase 3 study and how positive results from this trial may further shape the mantle cell lymphoma treatment landscape.
Read More
